FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula
or pharmaceutically acceptable salt thereof, synthesis methods thereof, pharmaceutical compositions containing said compounds, and use thereof to prepare a medicinal agent having mTOR kinase and/or PI3K kinase inhibiting action.
EFFECT: improved properties of the derivatives.
15 cl, 72 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOUNDS | 2020 |
|
RU2840815C2 |
| MORPHOLINO-SUBSTITUTED DERIVATIVES OF BICYCLIC PYRIMIDINE UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2609208C2 |
| PHOSPHOINOSITIDE-3-KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS | 2007 |
|
RU2437888C2 |
| IMMUNOMODULATORY AZALIDES BASED ON UREA | 2021 |
|
RU2811591C1 |
| 2-OXA-5-AZABICYCLO[2.2.1]HEPTANE-3-YL DERIVATIVES | 2015 |
|
RU2697651C2 |
| AZOLCARBOXAMIDE COMPOUND OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2008 |
|
RU2461551C2 |
| MORPHOLINE-PYRIDINE DERIVATIVES | 2015 |
|
RU2690154C2 |
| EMULSIFIABLE CONCENTRATE CONTAINING PESTICIDE, FATTY AMIDE AND LACTAMIDE | 2015 |
|
RU2688819C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
Authors
Dates
2012-01-20—Published
2007-08-21—Filed